This inventor holds 6 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Medimmune Limited. Active years: 2014-2022.
Company Filing History:
Years Active: 2014-2022
Title: Innovator Spotlight: Ross Anthony Stewart
Introduction:
Ross Anthony Stewart, a prolific inventor hailing from Cambridge, GB, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 6 patents, his work stands as a testament to his ingenuity and dedication to innovation.
Latest Patents:
Stewart's latest patents showcase his expertise in developing targeted binding agents against B7-H1 and GITRL fusion proteins. The former involves human monoclonal antibodies directed against B7-H1, offering potential applications in diagnostics and the treatment of diseases associated with B7-H1 activity. The latter patent focuses on GITRL fusion proteins that can self-assemble into hexameric proteins, showing promise in the treatment of cancer.
Career Highlights:
Ross Anthony Stewart is a key figure at Medimmune Limited, where he channels his inventive spirit into groundbreaking research and development. His patents reflect his commitment to pushing the boundaries of biotechnology and improving healthcare outcomes.
Collaborations:
Within Medimmune Limited, Stewart collaborates closely with esteemed colleagues such as Michelle Morrow and Christophe Queva. Together, they form a dynamic team driving innovation and advancing scientific knowledge in the field of biotechnology.
Conclusion:
In conclusion, Ross Anthony Stewart's groundbreaking work in developing targeted binding agents and fusion proteins exemplifies his prowess as an inventor. His patents not only demonstrate his technical expertise but also underscore his passion for making a meaningful impact in the realm of biotechnology.